French drugmaker Sanofi-Aventis could unveil an agreement to acquire U.S. biotech Genzyme before Wednesday, the day Sanofi is due to publish its 2010 results, sources close to the matter said.
A deal would bring to a close the long-running saga sparked by Genzyme’s rejection of Sanofi’s initial $18.5 billion offer, worth $69 a share, which the French group has extended to Feb. 15. Get the full story »
